nodes	percent_of_prediction	percent_of_DWPC	metapath
Toremifene—ESR1—uterine cancer	0.386	1	CbGaD
Toremifene—ESR1—Medroxyprogesterone Acetate—uterine cancer	0.177	0.377	CbGbCtD
Toremifene—ESR1—Progesterone—uterine cancer	0.117	0.25	CbGbCtD
Toremifene—CYP1A1—Progesterone—uterine cancer	0.0514	0.11	CbGbCtD
Toremifene—CYP1A2—Progesterone—uterine cancer	0.023	0.049	CbGbCtD
Toremifene—ABCB1—Progesterone—uterine cancer	0.0201	0.0428	CbGbCtD
Toremifene—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0182	0.0387	CbGbCtD
Toremifene—ABCB1—Dactinomycin—uterine cancer	0.0159	0.034	CbGbCtD
Toremifene—CYP3A4—Progesterone—uterine cancer	0.012	0.0257	CbGbCtD
Toremifene—CYP1A2—Etoposide—uterine cancer	0.0103	0.0219	CbGbCtD
Toremifene—ABCB1—Etoposide—uterine cancer	0.00899	0.0192	CbGbCtD
Toremifene—ABCB1—Doxorubicin—uterine cancer	0.00613	0.0131	CbGbCtD
Toremifene—CYP3A4—Etoposide—uterine cancer	0.00539	0.0115	CbGbCtD
Toremifene—CYP3A4—Doxorubicin—uterine cancer	0.00367	0.00783	CbGbCtD
Toremifene—ESR1—oviduct—uterine cancer	0.00237	0.156	CbGeAlD
Toremifene—Clomifene—CYP11A1—uterine cancer	0.000793	0.287	CrCbGaD
Toremifene—ESR1—myometrium—uterine cancer	0.000757	0.0501	CbGeAlD
Toremifene—ESR1—epithelium—uterine cancer	0.000594	0.0393	CbGeAlD
Toremifene—ESR1—uterine cervix—uterine cancer	0.000589	0.039	CbGeAlD
Toremifene—ESR1—smooth muscle tissue—uterine cancer	0.000572	0.0379	CbGeAlD
Toremifene—ESR1—decidua—uterine cancer	0.000561	0.0371	CbGeAlD
Toremifene—ESR1—renal system—uterine cancer	0.000551	0.0364	CbGeAlD
Toremifene—Ospemifene—ESR1—uterine cancer	0.000536	0.194	CrCbGaD
Toremifene—ESR1—endometrium—uterine cancer	0.000533	0.0352	CbGeAlD
Toremifene—ESR1—uterus—uterine cancer	0.000491	0.0325	CbGeAlD
Toremifene—CYP1A1—epithelium—uterine cancer	0.000452	0.0299	CbGeAlD
Toremifene—CYP1A1—uterine cervix—uterine cancer	0.000448	0.0296	CbGeAlD
Toremifene—ESR1—female reproductive system—uterine cancer	0.000441	0.0292	CbGeAlD
Toremifene—CYP1A2—renal system—uterine cancer	0.000425	0.0281	CbGeAlD
Toremifene—CYP1A1—renal system—uterine cancer	0.000419	0.0277	CbGeAlD
Toremifene—Clomifene—CYP19A1—uterine cancer	0.00041	0.148	CrCbGaD
Toremifene—ESR1—female gonad—uterine cancer	0.000402	0.0266	CbGeAlD
Toremifene—Sweating—Medroxyprogesterone Acetate—uterine cancer	0.0004	0.00379	CcSEcCtD
Toremifene—ESR1—vagina—uterine cancer	0.000399	0.0264	CbGeAlD
Toremifene—Visual impairment—Progesterone—uterine cancer	0.000398	0.00378	CcSEcCtD
Toremifene—Hepatobiliary disease—Medroxyprogesterone Acetate—uterine cancer	0.000395	0.00374	CcSEcCtD
Toremifene—CYP1A1—mammalian vulva—uterine cancer	0.000392	0.0259	CbGeAlD
Toremifene—Liver function test abnormal—Dactinomycin—uterine cancer	0.00039	0.0037	CcSEcCtD
Toremifene—Polyp—Epirubicin—uterine cancer	0.000388	0.00368	CcSEcCtD
Toremifene—Vaginal discharge—Epirubicin—uterine cancer	0.000388	0.00368	CcSEcCtD
Toremifene—Eye disorder—Progesterone—uterine cancer	0.000386	0.00366	CcSEcCtD
Toremifene—Clomifene—ESR1—uterine cancer	0.000377	0.137	CrCbGaD
Toremifene—Angiopathy—Progesterone—uterine cancer	0.000375	0.00356	CcSEcCtD
Toremifene—CYP1A1—uterus—uterine cancer	0.000373	0.0247	CbGeAlD
Toremifene—Mediastinal disorder—Progesterone—uterine cancer	0.000373	0.00353	CcSEcCtD
Toremifene—Embolism—Epirubicin—uterine cancer	0.000368	0.00349	CcSEcCtD
Toremifene—Alopecia—Progesterone—uterine cancer	0.000365	0.00346	CcSEcCtD
Toremifene—Mental disorder—Progesterone—uterine cancer	0.000362	0.00343	CcSEcCtD
Toremifene—Visual impairment—Medroxyprogesterone Acetate—uterine cancer	0.000361	0.00342	CcSEcCtD
Toremifene—Malnutrition—Progesterone—uterine cancer	0.00036	0.00341	CcSEcCtD
Toremifene—Vaginal discharge—Doxorubicin—uterine cancer	0.000359	0.0034	CcSEcCtD
Toremifene—Polyp—Doxorubicin—uterine cancer	0.000359	0.0034	CcSEcCtD
Toremifene—Cyst—Epirubicin—uterine cancer	0.000353	0.00335	CcSEcCtD
Toremifene—Eye disorder—Medroxyprogesterone Acetate—uterine cancer	0.00035	0.00332	CcSEcCtD
Toremifene—Back pain—Progesterone—uterine cancer	0.000348	0.0033	CcSEcCtD
Toremifene—Embolism—Doxorubicin—uterine cancer	0.00034	0.00323	CcSEcCtD
Toremifene—Angiopathy—Medroxyprogesterone Acetate—uterine cancer	0.00034	0.00322	CcSEcCtD
Toremifene—Hypercalcaemia—Epirubicin—uterine cancer	0.00034	0.00322	CcSEcCtD
Toremifene—Vision blurred—Progesterone—uterine cancer	0.000339	0.00321	CcSEcCtD
Toremifene—Mediastinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000338	0.0032	CcSEcCtD
Toremifene—Tremor—Progesterone—uterine cancer	0.000337	0.0032	CcSEcCtD
Toremifene—Chills—Medroxyprogesterone Acetate—uterine cancer	0.000336	0.00319	CcSEcCtD
Toremifene—CYP1A1—female reproductive system—uterine cancer	0.000336	0.0222	CbGeAlD
Toremifene—Thrombosis—Epirubicin—uterine cancer	0.000334	0.00316	CcSEcCtD
Toremifene—Alopecia—Medroxyprogesterone Acetate—uterine cancer	0.000331	0.00314	CcSEcCtD
Toremifene—Mental disorder—Medroxyprogesterone Acetate—uterine cancer	0.000328	0.00311	CcSEcCtD
Toremifene—Cyst—Doxorubicin—uterine cancer	0.000327	0.0031	CcSEcCtD
Toremifene—Malnutrition—Medroxyprogesterone Acetate—uterine cancer	0.000326	0.00309	CcSEcCtD
Toremifene—Vertigo—Progesterone—uterine cancer	0.000323	0.00306	CcSEcCtD
Toremifene—Vaginal haemorrhage—Epirubicin—uterine cancer	0.000319	0.00302	CcSEcCtD
Toremifene—Back pain—Medroxyprogesterone Acetate—uterine cancer	0.000315	0.00299	CcSEcCtD
Toremifene—Hypercalcaemia—Doxorubicin—uterine cancer	0.000314	0.00298	CcSEcCtD
Toremifene—Cardiac failure—Etoposide—uterine cancer	0.000313	0.00297	CcSEcCtD
Toremifene—Thrombosis—Doxorubicin—uterine cancer	0.000309	0.00293	CcSEcCtD
Toremifene—CYP3A4—renal system—uterine cancer	0.000307	0.0203	CbGeAlD
Toremifene—Chest pain—Progesterone—uterine cancer	0.000306	0.0029	CcSEcCtD
Toremifene—Tremor—Medroxyprogesterone Acetate—uterine cancer	0.000306	0.0029	CcSEcCtD
Toremifene—CYP1A1—female gonad—uterine cancer	0.000305	0.0202	CbGeAlD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.000304	0.00288	CcSEcCtD
Toremifene—CYP1A1—vagina—uterine cancer	0.000304	0.0201	CbGeAlD
Toremifene—ABCB1—myometrium—uterine cancer	0.000299	0.0198	CbGeAlD
Toremifene—Vaginal haemorrhage—Doxorubicin—uterine cancer	0.000295	0.0028	CcSEcCtD
Toremifene—Oedema—Progesterone—uterine cancer	0.000294	0.00278	CcSEcCtD
Toremifene—Vertigo—Medroxyprogesterone Acetate—uterine cancer	0.000293	0.00278	CcSEcCtD
Toremifene—Rigors—Epirubicin—uterine cancer	0.000289	0.00274	CcSEcCtD
Toremifene—Nervous system disorder—Progesterone—uterine cancer	0.000288	0.00273	CcSEcCtD
Toremifene—Skin disorder—Progesterone—uterine cancer	0.000285	0.0027	CcSEcCtD
Toremifene—Hyperhidrosis—Progesterone—uterine cancer	0.000284	0.00269	CcSEcCtD
Toremifene—Tamoxifen—ESR2—uterine cancer	0.000283	0.102	CrCbGaD
Toremifene—Anorexia—Progesterone—uterine cancer	0.00028	0.00265	CcSEcCtD
Toremifene—Chest pain—Medroxyprogesterone Acetate—uterine cancer	0.000278	0.00263	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.000276	0.00261	CcSEcCtD
Toremifene—Rigors—Doxorubicin—uterine cancer	0.000268	0.00254	CcSEcCtD
Toremifene—Oedema—Medroxyprogesterone Acetate—uterine cancer	0.000266	0.00252	CcSEcCtD
Toremifene—Insomnia—Progesterone—uterine cancer	0.000266	0.00252	CcSEcCtD
Toremifene—Chills—Dactinomycin—uterine cancer	0.000262	0.00249	CcSEcCtD
Toremifene—Dyspnoea—Progesterone—uterine cancer	0.000262	0.00248	CcSEcCtD
Toremifene—Skin discolouration—Epirubicin—uterine cancer	0.000261	0.00248	CcSEcCtD
Toremifene—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000261	0.00247	CcSEcCtD
Toremifene—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	0.000261	0.00247	CcSEcCtD
Toremifene—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.000259	0.00245	CcSEcCtD
Toremifene—Alopecia—Dactinomycin—uterine cancer	0.000258	0.00245	CcSEcCtD
Toremifene—ESR1—lymph node—uterine cancer	0.000258	0.0171	CbGeAlD
Toremifene—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.000257	0.00244	CcSEcCtD
Toremifene—Decreased appetite—Progesterone—uterine cancer	0.000255	0.00242	CcSEcCtD
Toremifene—Anorexia—Medroxyprogesterone Acetate—uterine cancer	0.000254	0.0024	CcSEcCtD
Toremifene—Gastrointestinal disorder—Progesterone—uterine cancer	0.000254	0.0024	CcSEcCtD
Toremifene—Fatigue—Progesterone—uterine cancer	0.000253	0.0024	CcSEcCtD
Toremifene—Constipation—Progesterone—uterine cancer	0.000251	0.00238	CcSEcCtD
Toremifene—Pain—Progesterone—uterine cancer	0.000251	0.00238	CcSEcCtD
Toremifene—CYP3A4—female reproductive system—uterine cancer	0.000246	0.0163	CbGeAlD
Toremifene—Skin discolouration—Doxorubicin—uterine cancer	0.000242	0.00229	CcSEcCtD
Toremifene—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.000241	0.00228	CcSEcCtD
Toremifene—Coordination abnormal—Epirubicin—uterine cancer	0.00024	0.00228	CcSEcCtD
Toremifene—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000237	0.00225	CcSEcCtD
Toremifene—Pulmonary embolism—Epirubicin—uterine cancer	0.000236	0.00224	CcSEcCtD
Toremifene—Hepatocellular injury—Epirubicin—uterine cancer	0.000236	0.00224	CcSEcCtD
Toremifene—ABCB1—epithelium—uterine cancer	0.000235	0.0155	CbGeAlD
Toremifene—ABCB1—uterine cervix—uterine cancer	0.000233	0.0154	CbGeAlD
Toremifene—Acute coronary syndrome—Etoposide—uterine cancer	0.000232	0.0022	CcSEcCtD
Toremifene—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.000231	0.00219	CcSEcCtD
Toremifene—Myocardial infarction—Etoposide—uterine cancer	0.000231	0.00219	CcSEcCtD
Toremifene—Neuropathy peripheral—Etoposide—uterine cancer	0.000231	0.00219	CcSEcCtD
Toremifene—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00023	0.00218	CcSEcCtD
Toremifene—Jaundice—Etoposide—uterine cancer	0.00023	0.00218	CcSEcCtD
Toremifene—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000229	0.00218	CcSEcCtD
Toremifene—Leukopenia—Dactinomycin—uterine cancer	0.000228	0.00216	CcSEcCtD
Toremifene—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000228	0.00216	CcSEcCtD
Toremifene—Hepatobiliary disease—Etoposide—uterine cancer	0.000223	0.00211	CcSEcCtD
Toremifene—Coordination abnormal—Doxorubicin—uterine cancer	0.000222	0.00211	CcSEcCtD
Toremifene—ABCB1—decidua—uterine cancer	0.000222	0.0147	CbGeAlD
Toremifene—Pulmonary embolism—Doxorubicin—uterine cancer	0.000218	0.00207	CcSEcCtD
Toremifene—Hepatocellular injury—Doxorubicin—uterine cancer	0.000218	0.00207	CcSEcCtD
Toremifene—Dry eye—Epirubicin—uterine cancer	0.000218	0.00207	CcSEcCtD
Toremifene—ABCB1—renal system—uterine cancer	0.000218	0.0144	CbGeAlD
Toremifene—Asthenia—Progesterone—uterine cancer	0.000211	0.002	CcSEcCtD
Toremifene—ABCB1—endometrium—uterine cancer	0.00021	0.0139	CbGeAlD
Toremifene—Pruritus—Progesterone—uterine cancer	0.000208	0.00197	CcSEcCtD
Toremifene—Oedema—Dactinomycin—uterine cancer	0.000208	0.00197	CcSEcCtD
Toremifene—Abnormal vision—Epirubicin—uterine cancer	0.000206	0.00195	CcSEcCtD
Toremifene—ABCB1—mammalian vulva—uterine cancer	0.000204	0.0135	CbGeAlD
Toremifene—Thrombocytopenia—Dactinomycin—uterine cancer	0.000203	0.00193	CcSEcCtD
Toremifene—Dry eye—Doxorubicin—uterine cancer	0.000202	0.00191	CcSEcCtD
Toremifene—Thrombophlebitis—Epirubicin—uterine cancer	0.000198	0.00188	CcSEcCtD
Toremifene—Anorexia—Dactinomycin—uterine cancer	0.000198	0.00188	CcSEcCtD
Toremifene—Eye disorder—Etoposide—uterine cancer	0.000198	0.00187	CcSEcCtD
Toremifene—CYP1A1—lymph node—uterine cancer	0.000196	0.013	CbGeAlD
Toremifene—Dizziness—Progesterone—uterine cancer	0.000194	0.00184	CcSEcCtD
Toremifene—ABCB1—uterus—uterine cancer	0.000194	0.0128	CbGeAlD
Toremifene—Angiopathy—Etoposide—uterine cancer	0.000192	0.00182	CcSEcCtD
Toremifene—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000191	0.00181	CcSEcCtD
Toremifene—Mediastinal disorder—Etoposide—uterine cancer	0.000191	0.00181	CcSEcCtD
Toremifene—Abnormal vision—Doxorubicin—uterine cancer	0.000191	0.00181	CcSEcCtD
Toremifene—Chills—Etoposide—uterine cancer	0.00019	0.0018	CcSEcCtD
Toremifene—Tamoxifen—CYP19A1—uterine cancer	0.00019	0.0686	CrCbGaD
Toremifene—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000188	0.00178	CcSEcCtD
Toremifene—Alopecia—Etoposide—uterine cancer	0.000187	0.00177	CcSEcCtD
Toremifene—Vomiting—Progesterone—uterine cancer	0.000187	0.00177	CcSEcCtD
Toremifene—Rash—Progesterone—uterine cancer	0.000185	0.00176	CcSEcCtD
Toremifene—Dermatitis—Progesterone—uterine cancer	0.000185	0.00175	CcSEcCtD
Toremifene—Headache—Progesterone—uterine cancer	0.000184	0.00174	CcSEcCtD
Toremifene—Hot flush—Epirubicin—uterine cancer	0.000183	0.00174	CcSEcCtD
Toremifene—Thrombophlebitis—Doxorubicin—uterine cancer	0.000183	0.00174	CcSEcCtD
Toremifene—Menopausal symptoms—Epirubicin—uterine cancer	0.000182	0.00172	CcSEcCtD
Toremifene—Decreased appetite—Dactinomycin—uterine cancer	0.00018	0.00171	CcSEcCtD
Toremifene—Fatigue—Dactinomycin—uterine cancer	0.000179	0.0017	CcSEcCtD
Toremifene—Back pain—Etoposide—uterine cancer	0.000178	0.00169	CcSEcCtD
Toremifene—Pain—Dactinomycin—uterine cancer	0.000178	0.00168	CcSEcCtD
Toremifene—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000176	0.00167	CcSEcCtD
Toremifene—Cardiac failure—Epirubicin—uterine cancer	0.000176	0.00166	CcSEcCtD
Toremifene—Lethargy—Epirubicin—uterine cancer	0.000175	0.00166	CcSEcCtD
Toremifene—Nausea—Progesterone—uterine cancer	0.000174	0.00165	CcSEcCtD
Toremifene—Tamoxifen—ESR1—uterine cancer	0.000174	0.0631	CrCbGaD
Toremifene—ABCB1—female reproductive system—uterine cancer	0.000174	0.0115	CbGeAlD
Toremifene—Diplopia—Epirubicin—uterine cancer	0.000171	0.00162	CcSEcCtD
Toremifene—Hot flush—Doxorubicin—uterine cancer	0.00017	0.00161	CcSEcCtD
Toremifene—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000169	0.0016	CcSEcCtD
Toremifene—Affect lability—Epirubicin—uterine cancer	0.000169	0.0016	CcSEcCtD
Toremifene—Menopausal symptoms—Doxorubicin—uterine cancer	0.000168	0.00159	CcSEcCtD
Toremifene—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000168	0.00159	CcSEcCtD
Toremifene—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000168	0.00159	CcSEcCtD
Toremifene—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000167	0.00158	CcSEcCtD
Toremifene—Vertigo—Etoposide—uterine cancer	0.000165	0.00157	CcSEcCtD
Toremifene—Leukopenia—Etoposide—uterine cancer	0.000165	0.00156	CcSEcCtD
Toremifene—Cardiac failure—Doxorubicin—uterine cancer	0.000162	0.00154	CcSEcCtD
Toremifene—Mood swings—Epirubicin—uterine cancer	0.000162	0.00154	CcSEcCtD
Toremifene—Lethargy—Doxorubicin—uterine cancer	0.000162	0.00153	CcSEcCtD
Toremifene—Ataxia—Epirubicin—uterine cancer	0.000161	0.00153	CcSEcCtD
Toremifene—ABCB1—female gonad—uterine cancer	0.000159	0.0105	CbGeAlD
Toremifene—Diplopia—Doxorubicin—uterine cancer	0.000159	0.0015	CcSEcCtD
Toremifene—Liver function test abnormal—Epirubicin—uterine cancer	0.000158	0.0015	CcSEcCtD
Toremifene—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000158	0.0015	CcSEcCtD
Toremifene—ABCB1—vagina—uterine cancer	0.000158	0.0104	CbGeAlD
Toremifene—Chest pain—Etoposide—uterine cancer	0.000157	0.00149	CcSEcCtD
Toremifene—Affect lability—Doxorubicin—uterine cancer	0.000156	0.00148	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000156	0.00148	CcSEcCtD
Toremifene—Breast disorder—Epirubicin—uterine cancer	0.000155	0.00147	CcSEcCtD
Toremifene—Mood swings—Doxorubicin—uterine cancer	0.00015	0.00142	CcSEcCtD
Toremifene—Ataxia—Doxorubicin—uterine cancer	0.000149	0.00141	CcSEcCtD
Toremifene—Asthenia—Dactinomycin—uterine cancer	0.000149	0.00141	CcSEcCtD
Toremifene—Thrombocytopenia—Etoposide—uterine cancer	0.000147	0.00139	CcSEcCtD
Toremifene—Liver function test abnormal—Doxorubicin—uterine cancer	0.000146	0.00139	CcSEcCtD
Toremifene—Skin disorder—Etoposide—uterine cancer	0.000146	0.00138	CcSEcCtD
Toremifene—Hyperhidrosis—Etoposide—uterine cancer	0.000145	0.00138	CcSEcCtD
Toremifene—Angina pectoris—Epirubicin—uterine cancer	0.000144	0.00137	CcSEcCtD
Toremifene—Breast disorder—Doxorubicin—uterine cancer	0.000143	0.00136	CcSEcCtD
Toremifene—Anorexia—Etoposide—uterine cancer	0.000143	0.00136	CcSEcCtD
Toremifene—Weight increased—Epirubicin—uterine cancer	0.000135	0.00128	CcSEcCtD
Toremifene—Dyspnoea—Etoposide—uterine cancer	0.000134	0.00127	CcSEcCtD
Toremifene—Angina pectoris—Doxorubicin—uterine cancer	0.000133	0.00127	CcSEcCtD
Toremifene—Vomiting—Dactinomycin—uterine cancer	0.000132	0.00125	CcSEcCtD
Toremifene—Rash—Dactinomycin—uterine cancer	0.000131	0.00124	CcSEcCtD
Toremifene—Decreased appetite—Etoposide—uterine cancer	0.000131	0.00124	CcSEcCtD
Toremifene—Gastrointestinal disorder—Etoposide—uterine cancer	0.00013	0.00123	CcSEcCtD
Toremifene—Fatigue—Etoposide—uterine cancer	0.00013	0.00123	CcSEcCtD
Toremifene—Neuropathy peripheral—Epirubicin—uterine cancer	0.000129	0.00123	CcSEcCtD
Toremifene—Jaundice—Epirubicin—uterine cancer	0.000129	0.00122	CcSEcCtD
Toremifene—Constipation—Etoposide—uterine cancer	0.000128	0.00122	CcSEcCtD
Toremifene—Pain—Etoposide—uterine cancer	0.000128	0.00122	CcSEcCtD
Toremifene—Sweating—Epirubicin—uterine cancer	0.000127	0.0012	CcSEcCtD
Toremifene—Hepatobiliary disease—Epirubicin—uterine cancer	0.000125	0.00118	CcSEcCtD
Toremifene—Weight increased—Doxorubicin—uterine cancer	0.000125	0.00118	CcSEcCtD
Toremifene—Nausea—Dactinomycin—uterine cancer	0.000123	0.00117	CcSEcCtD
Toremifene—Neuropathy peripheral—Doxorubicin—uterine cancer	0.00012	0.00114	CcSEcCtD
Toremifene—Jaundice—Doxorubicin—uterine cancer	0.000119	0.00113	CcSEcCtD
Toremifene—Sweating—Doxorubicin—uterine cancer	0.000117	0.00111	CcSEcCtD
Toremifene—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000116	0.0011	CcSEcCtD
Toremifene—Visual impairment—Epirubicin—uterine cancer	0.000114	0.00108	CcSEcCtD
Toremifene—Eye disorder—Epirubicin—uterine cancer	0.000111	0.00105	CcSEcCtD
Toremifene—Asthenia—Etoposide—uterine cancer	0.000108	0.00102	CcSEcCtD
Toremifene—Angiopathy—Epirubicin—uterine cancer	0.000108	0.00102	CcSEcCtD
Toremifene—Mediastinal disorder—Epirubicin—uterine cancer	0.000107	0.00101	CcSEcCtD
Toremifene—Chills—Epirubicin—uterine cancer	0.000106	0.00101	CcSEcCtD
Toremifene—Pruritus—Etoposide—uterine cancer	0.000106	0.00101	CcSEcCtD
Toremifene—Arrhythmia—Epirubicin—uterine cancer	0.000106	0.001	CcSEcCtD
Toremifene—Visual impairment—Doxorubicin—uterine cancer	0.000106	0.001	CcSEcCtD
Toremifene—Alopecia—Epirubicin—uterine cancer	0.000105	0.000993	CcSEcCtD
Toremifene—Mental disorder—Epirubicin—uterine cancer	0.000104	0.000984	CcSEcCtD
Toremifene—Malnutrition—Epirubicin—uterine cancer	0.000103	0.000978	CcSEcCtD
Toremifene—Eye disorder—Doxorubicin—uterine cancer	0.000103	0.000972	CcSEcCtD
Toremifene—ABCB1—lymph node—uterine cancer	0.000102	0.00674	CbGeAlD
Toremifene—Back pain—Epirubicin—uterine cancer	9.98e-05	0.000946	CcSEcCtD
Toremifene—Angiopathy—Doxorubicin—uterine cancer	9.95e-05	0.000943	CcSEcCtD
Toremifene—Dizziness—Etoposide—uterine cancer	9.94e-05	0.000942	CcSEcCtD
Toremifene—Mediastinal disorder—Doxorubicin—uterine cancer	9.89e-05	0.000937	CcSEcCtD
Toremifene—Chills—Doxorubicin—uterine cancer	9.84e-05	0.000933	CcSEcCtD
Toremifene—Arrhythmia—Doxorubicin—uterine cancer	9.8e-05	0.000929	CcSEcCtD
Toremifene—Vision blurred—Epirubicin—uterine cancer	9.73e-05	0.000922	CcSEcCtD
Toremifene—Alopecia—Doxorubicin—uterine cancer	9.69e-05	0.000919	CcSEcCtD
Toremifene—Mental disorder—Doxorubicin—uterine cancer	9.61e-05	0.000911	CcSEcCtD
Toremifene—Vomiting—Etoposide—uterine cancer	9.55e-05	0.000906	CcSEcCtD
Toremifene—Malnutrition—Doxorubicin—uterine cancer	9.55e-05	0.000905	CcSEcCtD
Toremifene—Rash—Etoposide—uterine cancer	9.47e-05	0.000898	CcSEcCtD
Toremifene—Dermatitis—Etoposide—uterine cancer	9.47e-05	0.000897	CcSEcCtD
Toremifene—Headache—Etoposide—uterine cancer	9.41e-05	0.000892	CcSEcCtD
Toremifene—Vertigo—Epirubicin—uterine cancer	9.27e-05	0.000879	CcSEcCtD
Toremifene—Leukopenia—Epirubicin—uterine cancer	9.24e-05	0.000876	CcSEcCtD
Toremifene—Back pain—Doxorubicin—uterine cancer	9.24e-05	0.000875	CcSEcCtD
Toremifene—Vision blurred—Doxorubicin—uterine cancer	9e-05	0.000853	CcSEcCtD
Toremifene—Nausea—Etoposide—uterine cancer	8.93e-05	0.000846	CcSEcCtD
Toremifene—Chest pain—Epirubicin—uterine cancer	8.79e-05	0.000833	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	8.73e-05	0.000827	CcSEcCtD
Toremifene—Vertigo—Doxorubicin—uterine cancer	8.58e-05	0.000813	CcSEcCtD
Toremifene—Leukopenia—Doxorubicin—uterine cancer	8.55e-05	0.00081	CcSEcCtD
Toremifene—Oedema—Epirubicin—uterine cancer	8.42e-05	0.000798	CcSEcCtD
Toremifene—Nervous system disorder—Epirubicin—uterine cancer	8.26e-05	0.000783	CcSEcCtD
Toremifene—Thrombocytopenia—Epirubicin—uterine cancer	8.25e-05	0.000782	CcSEcCtD
Toremifene—Skin disorder—Epirubicin—uterine cancer	8.18e-05	0.000775	CcSEcCtD
Toremifene—Hyperhidrosis—Epirubicin—uterine cancer	8.14e-05	0.000772	CcSEcCtD
Toremifene—Chest pain—Doxorubicin—uterine cancer	8.13e-05	0.000771	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	8.07e-05	0.000765	CcSEcCtD
Toremifene—Anorexia—Epirubicin—uterine cancer	8.03e-05	0.000761	CcSEcCtD
Toremifene—Oedema—Doxorubicin—uterine cancer	7.79e-05	0.000739	CcSEcCtD
Toremifene—Nervous system disorder—Doxorubicin—uterine cancer	7.64e-05	0.000724	CcSEcCtD
Toremifene—Thrombocytopenia—Doxorubicin—uterine cancer	7.63e-05	0.000723	CcSEcCtD
Toremifene—Insomnia—Epirubicin—uterine cancer	7.62e-05	0.000722	CcSEcCtD
Toremifene—Skin disorder—Doxorubicin—uterine cancer	7.57e-05	0.000717	CcSEcCtD
Toremifene—Hyperhidrosis—Doxorubicin—uterine cancer	7.53e-05	0.000714	CcSEcCtD
Toremifene—Dyspnoea—Epirubicin—uterine cancer	7.51e-05	0.000712	CcSEcCtD
Toremifene—Anorexia—Doxorubicin—uterine cancer	7.43e-05	0.000704	CcSEcCtD
Toremifene—ESR1—Regulation of Telomerase—CDKN1B—uterine cancer	7.38e-05	0.00345	CbGpPWpGaD
Toremifene—ESR1—Leptin signaling pathway—ERBB2—uterine cancer	7.37e-05	0.00345	CbGpPWpGaD
Toremifene—Decreased appetite—Epirubicin—uterine cancer	7.32e-05	0.000694	CcSEcCtD
Toremifene—CYP1A2—Metapathway biotransformation—AKR1B1—uterine cancer	7.32e-05	0.00343	CbGpPWpGaD
Toremifene—Gastrointestinal disorder—Epirubicin—uterine cancer	7.27e-05	0.000689	CcSEcCtD
Toremifene—Fatigue—Epirubicin—uterine cancer	7.26e-05	0.000688	CcSEcCtD
Toremifene—ESR1—ATF-2 transcription factor network—EP300—uterine cancer	7.26e-05	0.0034	CbGpPWpGaD
Toremifene—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	7.24e-05	0.00339	CbGpPWpGaD
Toremifene—ESR1—AP-1 transcription factor network—CDKN1B—uterine cancer	7.21e-05	0.00338	CbGpPWpGaD
Toremifene—ABCB1—HIF-1-alpha transcription factor network—SMAD3—uterine cancer	7.21e-05	0.00337	CbGpPWpGaD
Toremifene—Constipation—Epirubicin—uterine cancer	7.2e-05	0.000683	CcSEcCtD
Toremifene—Pain—Epirubicin—uterine cancer	7.2e-05	0.000683	CcSEcCtD
Toremifene—ESR1—Plasma membrane estrogen receptor signaling—PIK3CA—uterine cancer	7.19e-05	0.00336	CbGpPWpGaD
Toremifene—ESR1—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	7.13e-05	0.00334	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	7.11e-05	0.00333	CbGpPWpGaD
Toremifene—Insomnia—Doxorubicin—uterine cancer	7.05e-05	0.000668	CcSEcCtD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	6.97e-05	0.00326	CbGpPWpGaD
Toremifene—CYP1A1—Biological oxidations—CYP11A1—uterine cancer	6.97e-05	0.00326	CbGpPWpGaD
Toremifene—Dyspnoea—Doxorubicin—uterine cancer	6.95e-05	0.000659	CcSEcCtD
Toremifene—CYP1A1—Metapathway biotransformation—CYP11A1—uterine cancer	6.87e-05	0.00322	CbGpPWpGaD
Toremifene—ESR1—AP-1 transcription factor network—CTNNB1—uterine cancer	6.81e-05	0.00319	CbGpPWpGaD
Toremifene—ESR1—Validated nuclear estrogen receptor alpha network—EP300—uterine cancer	6.8e-05	0.00318	CbGpPWpGaD
Toremifene—Decreased appetite—Doxorubicin—uterine cancer	6.77e-05	0.000642	CcSEcCtD
Toremifene—Gastrointestinal disorder—Doxorubicin—uterine cancer	6.73e-05	0.000638	CcSEcCtD
Toremifene—Fatigue—Doxorubicin—uterine cancer	6.72e-05	0.000637	CcSEcCtD
Toremifene—ESR1—LKB1 signaling events—TP53—uterine cancer	6.69e-05	0.00313	CbGpPWpGaD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1B—uterine cancer	6.68e-05	0.00313	CbGpPWpGaD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	6.68e-05	0.00313	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—FGFR2—uterine cancer	6.67e-05	0.00312	CbGpPWpGaD
Toremifene—Constipation—Doxorubicin—uterine cancer	6.66e-05	0.000632	CcSEcCtD
Toremifene—Pain—Doxorubicin—uterine cancer	6.66e-05	0.000632	CcSEcCtD
Toremifene—ESR1—Plasma membrane estrogen receptor signaling—HRAS—uterine cancer	6.65e-05	0.00311	CbGpPWpGaD
Toremifene—ESR1—AP-1 transcription factor network—PTEN—uterine cancer	6.64e-05	0.00311	CbGpPWpGaD
Toremifene—CYP1A1—Metapathway biotransformation—AKR1C3—uterine cancer	6.49e-05	0.00304	CbGpPWpGaD
Toremifene—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	6.45e-05	0.00302	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	6.38e-05	0.00299	CbGpPWpGaD
Toremifene—ESR1—AP-1 transcription factor network—EP300—uterine cancer	6.33e-05	0.00296	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—uterine cancer	6.27e-05	0.00293	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	6.18e-05	0.00289	CbGpPWpGaD
Toremifene—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	6.15e-05	0.00288	CbGpPWpGaD
Toremifene—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	6.08e-05	0.00285	CbGpPWpGaD
Toremifene—ESR1—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	6.06e-05	0.00284	CbGpPWpGaD
Toremifene—Asthenia—Epirubicin—uterine cancer	6.04e-05	0.000573	CcSEcCtD
Toremifene—ESR1—Gene Expression—PHF1—uterine cancer	6e-05	0.00281	CbGpPWpGaD
Toremifene—Pruritus—Epirubicin—uterine cancer	5.96e-05	0.000565	CcSEcCtD
Toremifene—ESR1—Plasma membrane estrogen receptor signaling—AKT1—uterine cancer	5.87e-05	0.00275	CbGpPWpGaD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor—EP300—uterine cancer	5.87e-05	0.00275	CbGpPWpGaD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	5.87e-05	0.00275	CbGpPWpGaD
Toremifene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	5.86e-05	0.00274	CbGpPWpGaD
Toremifene—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	5.78e-05	0.00271	CbGpPWpGaD
Toremifene—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	5.65e-05	0.00264	CbGpPWpGaD
Toremifene—ESR1—Regulation of nuclear SMAD2/3 signaling—EP300—uterine cancer	5.63e-05	0.00264	CbGpPWpGaD
Toremifene—Asthenia—Doxorubicin—uterine cancer	5.59e-05	0.00053	CcSEcCtD
Toremifene—Dizziness—Epirubicin—uterine cancer	5.57e-05	0.000528	CcSEcCtD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	5.56e-05	0.0026	CbGpPWpGaD
Toremifene—Pruritus—Doxorubicin—uterine cancer	5.51e-05	0.000523	CcSEcCtD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	5.49e-05	0.00257	CbGpPWpGaD
Toremifene—CYP1A2—Metapathway biotransformation—AKR1C1—uterine cancer	5.37e-05	0.00252	CbGpPWpGaD
Toremifene—Vomiting—Epirubicin—uterine cancer	5.36e-05	0.000508	CcSEcCtD
Toremifene—Rash—Epirubicin—uterine cancer	5.31e-05	0.000503	CcSEcCtD
Toremifene—Dermatitis—Epirubicin—uterine cancer	5.31e-05	0.000503	CcSEcCtD
Toremifene—Headache—Epirubicin—uterine cancer	5.28e-05	0.0005	CcSEcCtD
Toremifene—Dizziness—Doxorubicin—uterine cancer	5.15e-05	0.000488	CcSEcCtD
Toremifene—CYP1A1—Biological oxidations—CYP19A1—uterine cancer	5.13e-05	0.0024	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—CHD4—uterine cancer	5.1e-05	0.00239	CbGpPWpGaD
Toremifene—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—uterine cancer	5.08e-05	0.00238	CbGpPWpGaD
Toremifene—CYP1A1—Metapathway biotransformation—CYP19A1—uterine cancer	5.05e-05	0.00237	CbGpPWpGaD
Toremifene—Nausea—Epirubicin—uterine cancer	5e-05	0.000474	CcSEcCtD
Toremifene—ESR1—Integrated Breast Cancer Pathway—CDH1—uterine cancer	4.99e-05	0.00234	CbGpPWpGaD
Toremifene—Vomiting—Doxorubicin—uterine cancer	4.96e-05	0.00047	CcSEcCtD
Toremifene—Rash—Doxorubicin—uterine cancer	4.91e-05	0.000466	CcSEcCtD
Toremifene—Dermatitis—Doxorubicin—uterine cancer	4.91e-05	0.000465	CcSEcCtD
Toremifene—Headache—Doxorubicin—uterine cancer	4.88e-05	0.000463	CcSEcCtD
Toremifene—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	4.75e-05	0.00222	CbGpPWpGaD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	4.73e-05	0.00221	CbGpPWpGaD
Toremifene—CYP1A2—Metapathway biotransformation—GPX3—uterine cancer	4.72e-05	0.00221	CbGpPWpGaD
Toremifene—Nausea—Doxorubicin—uterine cancer	4.63e-05	0.000439	CcSEcCtD
Toremifene—ESR1—AP-1 transcription factor network—TP53—uterine cancer	4.53e-05	0.00212	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	4.47e-05	0.00209	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—STAR—uterine cancer	4.47e-05	0.00209	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	4.47e-05	0.00209	CbGpPWpGaD
Toremifene—CYP1A2—Biological oxidations—CYP11A1—uterine cancer	4.44e-05	0.00208	CbGpPWpGaD
Toremifene—ESR1—Generic Transcription Pathway—PGR—uterine cancer	4.42e-05	0.00207	CbGpPWpGaD
Toremifene—CYP1A2—Metapathway biotransformation—CYP11A1—uterine cancer	4.38e-05	0.00205	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—SUZ12—uterine cancer	4.27e-05	0.002	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	4.26e-05	0.00199	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—uterine cancer	4.26e-05	0.00199	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—ERBB2—uterine cancer	4.19e-05	0.00196	CbGpPWpGaD
Toremifene—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	4.15e-05	0.00194	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	4.15e-05	0.00194	CbGpPWpGaD
Toremifene—CYP1A2—Metapathway biotransformation—AKR1C3—uterine cancer	4.14e-05	0.00194	CbGpPWpGaD
Toremifene—ESR1—Leptin signaling pathway—HRAS—uterine cancer	4.1e-05	0.00192	CbGpPWpGaD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	4.02e-05	0.00188	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	3.94e-05	0.00185	CbGpPWpGaD
Toremifene—ESR1—Regulation of Telomerase—AKT1—uterine cancer	3.92e-05	0.00183	CbGpPWpGaD
Toremifene—ESR1—Generic Transcription Pathway—ESR2—uterine cancer	3.89e-05	0.00182	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—CDKN1B—uterine cancer	3.88e-05	0.00182	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	3.76e-05	0.00176	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—EP300—uterine cancer	3.74e-05	0.00175	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	3.74e-05	0.00175	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—CTNNB1—uterine cancer	3.68e-05	0.00172	CbGpPWpGaD
Toremifene—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	3.64e-05	0.0017	CbGpPWpGaD
Toremifene—ESR1—Leptin signaling pathway—AKT1—uterine cancer	3.62e-05	0.00169	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—PTEN—uterine cancer	3.59e-05	0.00168	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—PTEN—uterine cancer	3.57e-05	0.00167	CbGpPWpGaD
Toremifene—ABCB1—Allograft Rejection—CXCL8—uterine cancer	3.55e-05	0.00166	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	3.54e-05	0.00166	CbGpPWpGaD
Toremifene—ABCB1—HIF-1-alpha transcription factor network—EP300—uterine cancer	3.51e-05	0.00164	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	3.5e-05	0.00164	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	3.49e-05	0.00163	CbGpPWpGaD
Toremifene—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	3.43e-05	0.0016	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—EP300—uterine cancer	3.42e-05	0.0016	CbGpPWpGaD
Toremifene—ESR1—Regulation of nuclear SMAD2/3 signaling—AKT1—uterine cancer	3.4e-05	0.00159	CbGpPWpGaD
Toremifene—ABCB1—Transmembrane transport of small molecules—ABCC9—uterine cancer	3.4e-05	0.00159	CbGpPWpGaD
Toremifene—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	3.38e-05	0.00158	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	3.37e-05	0.00158	CbGpPWpGaD
Toremifene—ABCB1—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	3.33e-05	0.00156	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	3.28e-05	0.00154	CbGpPWpGaD
Toremifene—CYP1A2—Biological oxidations—CYP19A1—uterine cancer	3.27e-05	0.00153	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—VEGFA—uterine cancer	3.24e-05	0.00152	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	3.23e-05	0.00151	CbGpPWpGaD
Toremifene—CYP1A2—Metapathway biotransformation—CYP19A1—uterine cancer	3.22e-05	0.00151	CbGpPWpGaD
Toremifene—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	3.19e-05	0.00149	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—NRAS—uterine cancer	3.19e-05	0.00149	CbGpPWpGaD
Toremifene—ESR1—Generic Transcription Pathway—CDKN2B—uterine cancer	3.17e-05	0.00148	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	3.05e-05	0.00143	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	3.01e-05	0.00141	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	2.97e-05	0.00139	CbGpPWpGaD
Toremifene—CYP1A1—PPARA activates gene expression—EP300—uterine cancer	2.92e-05	0.00137	CbGpPWpGaD
Toremifene—ESR1—Generic Transcription Pathway—SMAD3—uterine cancer	2.89e-05	0.00135	CbGpPWpGaD
Toremifene—ABCB1—Allograft Rejection—VEGFA—uterine cancer	2.88e-05	0.00135	CbGpPWpGaD
Toremifene—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—uterine cancer	2.86e-05	0.00134	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	2.85e-05	0.00133	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	2.85e-05	0.00133	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	2.84e-05	0.00133	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—KRAS—uterine cancer	2.76e-05	0.00129	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—NDUFB11—uterine cancer	2.75e-05	0.00129	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—SRD5A2—uterine cancer	2.75e-05	0.00129	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—KRAS—uterine cancer	2.74e-05	0.00128	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—AKR1B10—uterine cancer	2.7e-05	0.00127	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	2.69e-05	0.00126	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	2.68e-05	0.00125	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	2.56e-05	0.0012	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.53e-05	0.00118	CbGpPWpGaD
Toremifene—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	2.52e-05	0.00118	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—PIK3CA—uterine cancer	2.52e-05	0.00118	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	2.51e-05	0.00118	CbGpPWpGaD
Toremifene—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	2.49e-05	0.00116	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—TP53—uterine cancer	2.45e-05	0.00115	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—HRAS—uterine cancer	2.33e-05	0.00109	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	2.28e-05	0.00107	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—RNF43—uterine cancer	2.24e-05	0.00105	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—SRD5A2—uterine cancer	2.2e-05	0.00103	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—NDUFB11—uterine cancer	2.2e-05	0.00103	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—PGR—uterine cancer	2.13e-05	0.000996	CbGpPWpGaD
Toremifene—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	2.12e-05	0.000993	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	2.1e-05	0.000982	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	2.09e-05	0.000979	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—AKT1—uterine cancer	2.07e-05	0.000968	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—AKT1—uterine cancer	2.06e-05	0.000963	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—INHBA—uterine cancer	2.05e-05	0.000959	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	2.03e-05	0.00095	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—EZH2—uterine cancer	2.02e-05	0.000946	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—STAR—uterine cancer	1.99e-05	0.000932	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—AKR1B1—uterine cancer	1.99e-05	0.000932	CbGpPWpGaD
Toremifene—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—uterine cancer	1.97e-05	0.000922	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.97e-05	0.000921	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—ESR2—uterine cancer	1.87e-05	0.000877	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	1.85e-05	0.000864	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—AKR1C1—uterine cancer	1.84e-05	0.000863	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—NDUFB11—uterine cancer	1.76e-05	0.000822	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—SRD5A2—uterine cancer	1.76e-05	0.000822	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	1.71e-05	0.000802	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	1.71e-05	0.0008	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.71e-05	0.000798	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	1.61e-05	0.000756	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.61e-05	0.000754	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—STAR—uterine cancer	1.59e-05	0.000744	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—AKR1B1—uterine cancer	1.59e-05	0.000744	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	1.57e-05	0.000737	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—POLD1—uterine cancer	1.56e-05	0.000731	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—CDKN2B—uterine cancer	1.53e-05	0.000714	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	1.5e-05	0.000702	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—AKR1C1—uterine cancer	1.46e-05	0.000684	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	1.42e-05	0.000665	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—AKR1C3—uterine cancer	1.42e-05	0.000665	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—SMAD3—uterine cancer	1.39e-05	0.000652	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—PGR—uterine cancer	1.38e-05	0.000648	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—SRD5A2—uterine cancer	1.36e-05	0.000634	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—NDUFB11—uterine cancer	1.36e-05	0.000634	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—YWHAE—uterine cancer	1.32e-05	0.000618	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—RRM2—uterine cancer	1.3e-05	0.00061	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—AKR1B1—uterine cancer	1.27e-05	0.000594	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—STAR—uterine cancer	1.27e-05	0.000594	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—FBXW7—uterine cancer	1.27e-05	0.000592	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—DCN—uterine cancer	1.26e-05	0.000592	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.25e-05	0.000587	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—POLD1—uterine cancer	1.25e-05	0.000584	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.21e-05	0.000566	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—CYP11A1—uterine cancer	1.19e-05	0.000558	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—AKR1C1—uterine cancer	1.17e-05	0.000546	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—AKR1C3—uterine cancer	1.13e-05	0.000527	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.11e-05	0.00052	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—STK11—uterine cancer	1.11e-05	0.000518	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.07e-05	0.000503	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—RRM2—uterine cancer	1.04e-05	0.000487	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—SOCS3—uterine cancer	1.04e-05	0.000485	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—DCN—uterine cancer	1.01e-05	0.000473	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—POLD1—uterine cancer	9.96e-06	0.000466	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—CDKN2B—uterine cancer	9.92e-06	0.000464	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—AKR1B1—uterine cancer	9.8e-06	0.000459	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—STAR—uterine cancer	9.8e-06	0.000459	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—IGF1R—uterine cancer	9.63e-06	0.000451	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—CYP11A1—uterine cancer	9.52e-06	0.000445	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—AKR1C1—uterine cancer	9.32e-06	0.000436	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	9.07e-06	0.000425	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—SMAD3—uterine cancer	9.06e-06	0.000424	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—AKR1C3—uterine cancer	8.99e-06	0.000421	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—CYP19A1—uterine cancer	8.76e-06	0.00041	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—STK11—uterine cancer	8.76e-06	0.00041	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—FGFR2—uterine cancer	8.64e-06	0.000404	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—RRM2—uterine cancer	8.31e-06	0.000389	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	8.23e-06	0.000385	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—DCN—uterine cancer	8.06e-06	0.000377	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	7.85e-06	0.000367	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—POLD1—uterine cancer	7.69e-06	0.00036	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—CYP11A1—uterine cancer	7.6e-06	0.000356	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—AKR1C1—uterine cancer	7.19e-06	0.000337	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—AKR1C3—uterine cancer	7.17e-06	0.000336	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—STK11—uterine cancer	7e-06	0.000328	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—CYP19A1—uterine cancer	7e-06	0.000328	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—MTHFR—uterine cancer	6.59e-06	0.000308	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—CCL2—uterine cancer	6.51e-06	0.000305	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—RRM2—uterine cancer	6.41e-06	0.0003	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—DCN—uterine cancer	6.22e-06	0.000291	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—CYP11A1—uterine cancer	5.86e-06	0.000274	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.8e-06	0.000272	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—STK11—uterine cancer	5.59e-06	0.000262	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—CYP19A1—uterine cancer	5.59e-06	0.000262	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—AKR1C3—uterine cancer	5.54e-06	0.000259	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—ERBB2—uterine cancer	5.42e-06	0.000254	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—MTHFR—uterine cancer	5.26e-06	0.000246	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.25e-06	0.000246	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—CXCL8—uterine cancer	5.14e-06	0.000241	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—CDKN1B—uterine cancer	5.02e-06	0.000235	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5e-06	0.000234	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—CTNNB1—uterine cancer	4.75e-06	0.000222	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—PTEN—uterine cancer	4.63e-06	0.000216	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—EP300—uterine cancer	4.41e-06	0.000206	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—CYP19A1—uterine cancer	4.31e-06	0.000202	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—STK11—uterine cancer	4.31e-06	0.000202	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—MTHFR—uterine cancer	4.2e-06	0.000197	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—VEGFA—uterine cancer	4.18e-06	0.000196	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—NRAS—uterine cancer	4.13e-06	0.000193	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—AKT1—uterine cancer	4.1e-06	0.000192	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.7e-06	0.000173	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—PTEN—uterine cancer	3.66e-06	0.000172	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—KRAS—uterine cancer	3.55e-06	0.000166	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—EP300—uterine cancer	3.49e-06	0.000164	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—PIK3CA—uterine cancer	3.26e-06	0.000153	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—MTHFR—uterine cancer	3.24e-06	0.000152	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—TP53—uterine cancer	3.16e-06	0.000148	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—HRAS—uterine cancer	3.02e-06	0.000141	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—PTEN—uterine cancer	2.93e-06	0.000137	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—EP300—uterine cancer	2.79e-06	0.000131	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—AKT1—uterine cancer	2.67e-06	0.000125	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—PIK3CA—uterine cancer	2.58e-06	0.000121	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—PTEN—uterine cancer	2.34e-06	0.000109	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—EP300—uterine cancer	2.23e-06	0.000104	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—AKT1—uterine cancer	2.11e-06	9.88e-05	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—PIK3CA—uterine cancer	2.06e-06	9.66e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—PTEN—uterine cancer	1.8e-06	8.44e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—EP300—uterine cancer	1.72e-06	8.05e-05	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—AKT1—uterine cancer	1.69e-06	7.89e-05	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—PIK3CA—uterine cancer	1.65e-06	7.71e-05	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—AKT1—uterine cancer	1.35e-06	6.3e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.27e-06	5.95e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—AKT1—uterine cancer	1.04e-06	4.86e-05	CbGpPWpGaD
